Fortress Biotech (FBIO) Hisse Özeti
Fortress Biotech, Inc. iştirakleriyle birlikte Amerika Birleşik Devletleri'nde ve uluslararası alanda bir biyofarmasötik şirketi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
FBIO Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fortress Biotech, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$2.78 |
| 52 Haftanın En Yüksek Seviyesi | US$4.53 |
| 52 Haftanın En Düşük Seviyesi | US$1.67 |
| Beta | 1.16 |
| 1 Aylık Değişim | 24.66% |
| 3 Aylık Değişim | -17.26% |
| 1 Yıllık Değişim | 60.69% |
| 3 Yıllık Değişim | -62.25% |
| 5 Yıllık Değişim | -95.12% |
| Halka arzdan bu yana değişim | -98.32% |
Son Haberler & Güncellemeler
Recent updates
FBIO: Rare Pediatric Disease Voucher Will Support Future Upside Potential
Analysts have lifted their Fortress Biotech price target to $4.50 from $4.50, supported by updated assumptions around a slightly lower discount rate, adjusted revenue growth, an improved profit margin outlook, and a reduced future P/E multiple. Valuation Changes Fair Value: $4.50 is unchanged, with the target level held steady versus prior estimates.FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around a fair value of $4.50, a discount rate of 8.80%, revenue growth of 44.56%, a profit margin of 12.79% and a future P/E of 9.24. Valuation Changes Fair Value: Maintained at $4.50, with no change in the estimated fair value per share.FBIO: Rare Pediatric Disease Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech to reflect updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. This has led to a revised target that is intended to better align with the company’s current risk and earnings outlook.FBIO: Menkes Disease Breakthrough And Voucher Will Drive Future Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech to $4.50, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, while keeping the overall fair value view steady. What's in the News FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, marking the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).FBIO: Menkes Disease Approval And Voucher Will Drive Future Upside Potential
Analysts have adjusted their price target on Fortress Biotech, maintaining it at $4.50, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions that continue to support a similar fair value estimate. What's in the News Fortress Biotech and majority owned subsidiary Cyprium Therapeutics received FDA approval for ZYCUBO (copper histidinate, formerly CUTX-101) to treat Menkes disease in pediatric patients, the first and only FDA approved treatment for this rare and often fatal condition (Key Developments).FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Support Upside Potential
Analysts have modestly adjusted their price target on Fortress Biotech, reflecting updated views on revenue growth, profit margins, and future P/E assumptions, while keeping the underlying fair value estimate steady at $4.50. What's in the News The U.S. FDA approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients.Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap
Summary Fortress Biotech is essentially a holding company biotech with a dermatology revenue base (Journey Medical). However, FBIO’s subsidiaries give it optionality across multiple subsidiaries, equity stakes, and royalty streams. FBIO’s Journey Medical assets give it its branded dermatology portfolio. The newly approved Emrosi provides near-term revenues. But more importantly, Zycubo (CUTX-101) for Menkes disease was FDA-approved in January 2026. This created a Rare Pediatric Disease PRV for FBIO. PRVs can be extremely valuable, and given FBIO’s microcap status, it could be a major upside catalyst if they sell it at a good price. Read the full article on Seeking AlphaFBIO: Menkes Disease Approval And Voucher Potential Will Drive Bullish Upside
Analysts have nudged their price target on Fortress Biotech higher to $4.50, reflecting updated assumptions around revenue growth, profit margins, and a slightly lower discount rate that together indicate a modestly stronger outlook for the company. What's in the News The U.S. Food and Drug Administration approved ZYCUBO (copper histidinate, formerly CUTX-101) for treating Menkes disease in pediatric patients, the first and only FDA approved therapy for this rare and often fatal condition (Key Developments).Market Cool On Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Pushing Shares 28% Lower
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares have retraced a considerable 28% in the last month, reversing a fair...FBIO: Menkes Disease Breakthrough And Voucher Opportunity Will Drive Bullish Outlook
Analysts have adjusted their price target on Fortress Biotech, reflecting updated assumptions on a discount rate, a profit margin of 65.99% and a future P/E of 1.53x. They are tying the change to a revised view of the company’s earnings power and risk profile.FBIO: Resubmitted Menkes Therapy And Voucher Potential Will Shape Balanced Outlook
Analysts have adjusted their price target on Fortress Biotech to US$4.50, with the update mainly tied to refreshed assumptions around the discount rate, revenue growth near 48.3%, profit margin around 16.2% and a future P/E of about 6.17x. What's in the News Fortress Biotech and majority-owned subsidiary Cyprium Therapeutics had the resubmission of the New Drug Application for CUTX-101, a copper histidinate therapy for pediatric Menkes disease, accepted by the U.S. FDA as a Class 1 resubmission, with a new PDUFA target action date of January 14, 2026 (company announcement).FBIO: FDA Progress On Rare Disease Therapy Will Drive Significant Upside Potential
Analysts have modestly lifted their price target on Fortress Biotech to $4.50 per share, citing slightly lower perceived risk, marginally stronger long term revenue growth, and a small improvement in projected profitability that together support a higher justified valuation multiple. What's in the News FDA accepts resubmission of the New Drug Application for CUTX-101 for Menkes disease as a Class 1 resubmission, setting a new PDUFA target action date of January 14, 2026 (Key Developments) Earlier FDA Complete Response Letter for CUTX-101 cited cGMP compliance issues at the manufacturing site but raised no concerns with the drug's efficacy or safety data (Key Developments) Sentynl Therapeutics now holds full responsibility for development and commercialization of CUTX-101, with Cyprium eligible for royalties, up to $129 million in milestones, and a potential Rare Pediatric Disease Priority Review Voucher upon approval (Key Developments) CUTX-101 NDA, initially granted Priority Review, is supported by positive topline data showing significant improvement in overall survival in Menkes disease patients treated early (Key Developments) Valuation Changes Fair Value: unchanged at $4.50 per share, reflecting a stable central valuation despite minor model adjustments Discount Rate: decreased slightly from 8.36 percent to 8.07 percent, indicating a modest reduction in perceived risk Revenue Growth: increased slightly from 46.90 percent to 47.54 percent, reflecting marginally stronger long term growth expectations Net Profit Margin: increased slightly from 16.03 percent to 16.24 percent, pointing to a small improvement in projected profitability Future P/E: declined modestly from 6.51x to 6.29x, suggesting a slightly lower multiple applied to future earningsInvestors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 27% in...FBIO: Menkes Drug Clearance Of Manufacturing Issues Will Unlock Significant Upside Potential
Analysts have modestly raised their price target on Fortress Biotech to reflect a slightly higher fair value estimate of $4.50 per share, supported by expectations for stronger revenue growth and only a modest adjustment to discount rates and future valuation multiples. What's in the News The FDA issued a Complete Response Letter for the CUTX-101 New Drug Application for Menkes disease, citing cGMP deficiencies at the manufacturing facility but raising no concerns about efficacy or safety data.Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive
The Fortress Biotech, Inc. ( NASDAQ:FBIO ) share price has softened a substantial 26% over the previous 30 days...
FDA Approval Will Open $1 Billion Dermatology Market
Despite increased revenue growth forecasts, Fortress Biotech’s consensus price target was lowered from $10.00 to $8.00 amid a sharply reduced future P/E, indicating a more cautious outlook on profitability relative to anticipated sales growth. What's in the News Fortress Biotech was dropped from the Russell Microcap Growth Benchmark Index.Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks
With a price-to-sales (or "P/S") ratio of 1.1x Fortress Biotech, Inc. ( NASDAQ:FBIO ) may be sending very bullish...FDA Approval Will Open $1 Billion Dermatology Market
Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy...Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry
Those holding Fortress Biotech, Inc. ( NASDAQ:FBIO ) shares would be relieved that the share price has rebounded 36% in...Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders have had their patience rewarded with a 54% share price jump in the...There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Fortress Biotech, Inc. ( NASDAQ:FBIO ) shareholders are no doubt pleased to see that the share price has bounced 99% in...There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Fortress Biotech, Inc.'s ( NASDAQ:FBIO ) price-to-sales (or "P/S") ratio of 0.9x might make it look like a strong buy...Hissedar Getirileri
| FBIO | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 20.9% | -1.6% | -0.8% |
| 1Y | 60.7% | 34.4% | 27.1% |
Getiri vs. Endüstri: FBIO geçen yıl % 34.4 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: FBIO geçen yıl % 27.1 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| FBIO volatility | |
|---|---|
| FBIO Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: FBIO son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: FBIO 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2006 | 78 | Lindsay Rosenwald | www.fortressbiotech.com |
Fortress Biotech, Inc. iştirakleri ile birlikte Amerika Birleşik Devletleri'nde ve uluslararası alanda bir biyofarmasötik şirketi olarak faaliyet göstermektedir. Şirket, rosacea tedavisi için bir minosiklin hidroklorür uzatılmış salımlı kapsül olan Emrosi'yi; aksiller hiperhidroz tedavisi için ilaçlı bir bez havlu olan Qbrexza'yı sunmaktadır; Accutane, şiddetli inatçı nodüler akne tedavisi için oral bir izotretinoin ilacı; Amzeeq, nodüler olmayan orta ila şiddetli akne vulgaris lezyonlarının tedavisi için bir minosiklin topikal köpük; Zilxi, rosacea lezyonlarının tedavisi için bir minosiklin topikal köpük; Exelderm, topikal kullanım için bir antifungal krem; Targadox, şiddetli akne tedavisi için bir oral doksisiklin ilacı; Luxamend, yüzeysel yaralar, küçük kesikler veya sıyrıklar, dermal ülserler, donör bölgeler, birinci ve ikinci derece yanıklar ve radyasyon dermatitinin tedavisi için su bazlı bir emülsiyon; ve UNLOXCYT, metastatik kutanöz skuamöz hücreli karsinom tedavisi için bir ölüm-ligand 1 bloke edici antikor. Ayrıca Menkes hastalığının tedavisi için FDA onayı aşamasında olan bakır histidinat enjeksiyonu CUTX-101'i; ameliyat sonrası akut ağrının tedavisi için NDA/BLA dosyalanma aşamasında olan intravenöz bir formülasyon olan IV Tramadol'ü; gut ve kronik böbrek hastalıklarının tedavisi için Faz III aşamasında olan bir ürat taşıyıcı inhibitörü olan Dotinurad'ı geliştirmektedir; Amiloid hafif zincir amiloidozunun tedavisi için Faz III aşamasında olan hafif zincir fibril-reaktif monoklonal antikor CAEL-101; ve sitomegalovirüs, anti-insan immün yetmezlik virüsü, non-hodgkin lenfoma ve akut lenfoblastik lösemi tedavisi için Faz II aşamasında olan evrensel rekombinant modifiye vaccinia ankara viral vektör aşısı Triplex.
Fortress Biotech, Inc. Temel Bilgiler Özeti
| FBIO temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$88.03m |
| Kazançlar(TTM) | US$119.20m |
| Gelir(TTM) | US$66.16m |
FBIO aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| FBIO gelir tablosu (TTM) | |
|---|---|
| Gelir | US$66.16m |
| Gelir Maliyeti | US$34.25m |
| Brüt Kâr | US$31.91m |
| Diğer Giderler | -US$87.29m |
| Kazançlar | US$119.20m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 3.59 |
| Brüt Marj | 48.23% |
| Net Kâr Marjı | 180.16% |
| Borç/Özkaynak Oranı | 19.5% |
FBIO uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/21 18:18 |
| Gün Sonu Hisse Fiyatı | 2026/05/21 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Fortress Biotech, Inc. 13 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Scott Henry | Alliance Global Partners |
| Stephen V. Byrne | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |